Summit Therapeutics (SMMT) Set to Announce Earnings on Monday

Summit Therapeutics (NASDAQ:SMMT) is expected to post its Q3 2026 results after the market closes on Monday, October 19th. Analysts expect Summit Therapeutics to post earnings of ($0.2806) per share and revenue of $0.07 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, October 19, 2026 at 8:00 AM ET.

Summit Therapeutics (NASDAQ:SMMT) last issued its earnings results on Thursday, July 23rd. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts expect Summit Therapeutics to post ($1.20) EPS for the current fiscal year and ($1.25) EPS for the next fiscal year.

Summit Therapeutics Trading Down 4.8%

Shares of Summit Therapeutics stock opened at $14.63 on Friday. The stock has a market capitalization of $11.70 billion, a price-to-earnings ratio of -13.06 and a beta of -1.51. Summit Therapeutics has a 1-year low of $12.07 and a 1-year high of $29.23. The firm’s 50-day moving average price is $15.75 and its two-hundred day moving average price is $16.37.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on SMMT shares. Morgan Stanley lowered Summit Therapeutics to an “outperform” rating in a research note on Tuesday, September 29th. Summit Redstone set a $25.00 target price on shares of Summit Therapeutics in a research note on Wednesday, September 9th. Leerink Partners upgraded shares of Summit Therapeutics from an “underperform” rating to a “market perform” rating and upped their target price for the stock from $12.00 to $13.00 in a research report on Wednesday, August 12th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Summit Therapeutics in a research report on Monday, October 5th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $30.00 price target on shares of Summit Therapeutics in a research note on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Summit Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $28.61.

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments. The company’s lead program is ivonescimab, an investigational bispecific antibody designed to combine immune checkpoint inhibition targeting PD-1 with anti-angiogenic activity targeting VEGF. Summit is evaluating ivonescimab in clinical studies for multiple solid tumors, including non-small cell lung cancer.

Summit obtained exclusive rights from Akeso, Inc to develop and commercialize ivonescimab in markets outside China, including the United States and other international territories.